VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Zelenetz on Potential of Acalabrutinib and BGB-3111 in CLL

Andrew D. Zelenetz, MD, PhD
Published: Tuesday, Apr 18, 2017



Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib and BGB-3111 are described by Zelenetz as "pseudo" next-generation drugs, as they both have similar mechanisms of action. Additionally, they both bind to the active site cysteine and covalently modify the drug.

Moreover, it is known that acalabrutinib and BGB-3111 do not interfere with antibody-dependent cell-mediated cytotoxicity in culture. Therefore, they should play better in vivo with monoclonal antibodies but this has to be proven. Zelenetz adds that there should be fewer T-cell effects with both agents, and that they can achieve high levels of occupancy of BTK and are very active in patients with CLL.
 


Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib and BGB-3111 are described by Zelenetz as "pseudo" next-generation drugs, as they both have similar mechanisms of action. Additionally, they both bind to the active site cysteine and covalently modify the drug.

Moreover, it is known that acalabrutinib and BGB-3111 do not interfere with antibody-dependent cell-mediated cytotoxicity in culture. Therefore, they should play better in vivo with monoclonal antibodies but this has to be proven. Zelenetz adds that there should be fewer T-cell effects with both agents, and that they can achieve high levels of occupancy of BTK and are very active in patients with CLL.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x